Optimizing the Therapeutic Ratio in Prostate Radiation Therapy

Prostate cancer has long served as a prominent ground for innovation in cancer therapy. Localized prostate cancer occupies a unique clinical position because, despite a high incidence of new diagnoses, it often follows an indolent course. Consequently, the risk of prostate cancer–specific mortality remains generally low. For appropriately selected patients, multiple management strategies exist, including surgery, radiation therapy, and active surveillance. These different approaches yield similar disease outcomes in well-chosen men. Treatment decisions for localized disease must therefore consider not only oncologic efficacy, but also the preservation of urinary, bowel, and sexual function. Over the past several decades, advances in imaging, genomic risk stratification, and treatment delivery have steadily transformed patient care. The shared goal of clinicians and researchers is to optimize the therapeutic ratio by maintaining high rates of cancer control while minimizing treatment-related side effects.